11 unknown, 4 recruiting, 3 active not recruiting, 3 completed. 12 Phase 2, 3 Phase 4, 2 Phase 1, 1 Early Phase 1, 1 Not applicable.
Follow EGFR Positive Non-small Cell Lung Cancer: new trials by email Literature Review of EGFR Positive Non-small Cell Lung Cancer trials Research Report on EGFR Positive Non-small Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Firmonertinib Plus Chemotherapy for Unresectable EGFR PACC-Mutant Stage III Lung Cancer: A Phase II Study Firmonertinib, Platinum-based chemotherapy - Lung Adenocarcinoma, Stage III Lung Cancer | Phase 2 | Not yet recruiting | Hunan Province Tumor Hospital | 27 | 2026-11-01 | 2026-10-16 |
| Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma Firmonertinib 80mg qd oral for 8 weeks., Firmonertinib 160mg qd oral for 8 weeks., Firmonertinib 80mg qd oral for 16 weeks. - NSCLC, EGFR Positive Non-small Cell Lung Cancer | Phase 2 | Recruiting | Peking University Cancer Hospital & Institute | 60 | 2026-09-03 | 2026-10-27 |
| Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg Firmonertinib 160mg - NSCLC Stage IV, EGFR Positive Non-small Cell Lung Cancer | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 28 | 2026-01-01 | 2026-01-21 |
| Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification • Drug: Savolitinib • Drug: Osimertinib Mesylate Tablets - EGFR Positive Non-small Cell Lung Cancer, MET Amplification | Phase 2 | Recruiting | Qingdao Central Hospital | 60 | 2025-01-01 | 2026-01-07 |
| SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC) SMET12 - EGFR Positive Non-small Cell Lung Cancer | Early Phase 1 | Unknown | Fujian Cancer Hospital | 40 | 2024-01-10 | 2024-01-17 |
| Patient-centered, Optimal Integration of Survivorship and Palliative Care POISE - Stage IV Non-small Cell Lung Cancer, Targeted Therapy | Not applicable | Recruiting | Massachusetts General Hospital | 70 | 2023-09-29 | 2025-11-24 |
| Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation Toripalimab plus Chemotherapy - Non Squamous Non Small Cell Lung Cancer, EGFR Positive Non-small Cell Lung Cancer | Phase 2 | Unknown | Peking University People's Hospital | 126 | 2023-08-01 | 2023-08-01 |
| A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy Lazertinib - Non-small Cell Lung Cancer Stage III, EGFR Positive Non-small Cell Lung Cancer | Phase 2 | Unknown | Sung Yong Lee | 77 | 2022-06-30 | 2023-09-01 |
| Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study Osimertinib, Radiotherapy - NSCLC, EGFR Positive Non-small Cell Lung Cancer | Phase 2 | Active not recruiting | AIO-Studien-gGmbH | 42 | 2022-01-20 | 2026-01-14 |
| Osimertinib for Advanced EGFR-positive NSCLC Patients EGFR Positive Non-small Cell Lung Cancer, Non Small Cell Lung Cancer | Recruiting | National University Hospital, Singapore | 58 | 2021-07-22 | 2025-09-25 | |
| A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases Almonertinib - EGFR Positive Non-small Cell Lung Cancer, Brain Metastases | Phase 2 | Unknown | First People's Hospital of Hangzhou | 47 | 2020-11-30 | 2020-11-25 |
| Firmonertinib in the Treatment of EGFR(+) NSCLC Patients With Central Nervous System Metastasis Firmonertinib - EGFR Positive Non-small Cell Lung Cancer, Central Nervous System Metastasis | Completed | Beijing Tiantan Hospital | 300 | 2020-01-01 | 2025-11-20 | |
| Phase 2 Study of Dacomitinib in NSCLC Dacomitinib - NSCLC Stage IIIB, NSCLC Stage IIIC | Phase 2 | Active not recruiting | National Cancer Centre, Singapore | 118 | 2019-09-11 | 2025-06-12 |
| A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients APG-1252, Osimertinib Mesylate Tablets - EGFR Positive Non-small Cell Lung Cancer | Phase 1 | Active not recruiting | Ascentage Pharma Group Inc. | 80 | 2019-07-04 | 2025-10-01 |
| Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLC EGFR Positive Non-small Cell Lung Cancer | Completed | Thoraxklinik-Heidelberg gGmbH | 400 | 2019-04-15 | 2023-11-22 | |
| Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients EGFR - EGFR Positive Non-small Cell Lung Cancer | Phase 2 | Unknown | Korea University Guro Hospital | 63 | 2018-01-03 | 2021-07-15 |
| First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors TP-0903 - Advanced Solid Tumors, EGFR Positive Non-small Cell Lung Cancer | Phase 1 | Completed | Sumitomo Pharma America, Inc. | 177 | 2016-12-14 | 2023-11-14 |
| A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+) Erlotinib plus Bevacizumab, Erlotinib - EGFR Positive Non-small Cell Lung Cancer | Phase 2 | Unknown | National Cancer Center, Korea | 128 | 2016-11-01 | 2022-04-06 |
| A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy EGFR-TKI, Thoracic Hypofractionated Radiotherapy - Lung Adenocarcinoma, EGFR Positive Non-small Cell Lung Cancer | Phase 2 | Unknown | First People's Hospital of Hangzhou | 76 | 2016-05-01 | 2016-06-02 |
| Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma Icotinib, Placebo - EGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma | Phase 3 | Unknown | Betta Pharmaceuticals Co., Ltd. | 124 | 2014-09-01 | 2018-07-16 |
Showing 20 of 23. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (6) · Adenocarcinoma (4) · Adenocarcinoma of Lung (2) · Brain Neoplasms (1) · Colorectal Neoplasms (1) · Lung Neoplasms (1) · Meningeal Carcinomatosis (1) · Neoplasms (1) · Ovarian Neoplasms (1)
Neoplasms (14) · Neoplasms by Site (11) · Respiratory Tract Neoplasms (8) · Thoracic Neoplasms (8) · Lung Diseases (7) · Lung Neoplasms (7) · Respiratory Tract Diseases (7) · Bronchial Neoplasms (6) · Carcinoma (6) · Carcinoma, Bronchogenic (6) · Neoplasms by Histologic Type (6) · Neoplasms, Glandular and Epithelial (6) · Adenocarcinoma (2) · Central Nervous System Neoplasms (2) · Nervous System Diseases (2)
Drug Therapy (3) · Pemetrexed (3) · Docetaxel (2) · icotinib (2) · osimertinib (2) · toripalimab (2) · Bevacizumab (1) · Carboplatin (1) · Cisplatin (1) · Erlotinib Hydrochloride (1) · Gefitinib (1) · Gemcitabine (1) · Injections (1) · Paclitaxel (1) · Platinum Compounds (1)
Betta Pharmaceuticals Co., Ltd. (4) · First People's Hospital of Hangzhou (2) · Peking University Cancer Hospital & Institute (2) · AIO-Studien-gGmbH (1) · Ascentage Pharma Group Inc. (1) · Beijing Tiantan Hospital (1) · Fujian Cancer Hospital (1) · Hunan Province Tumor Hospital (1) · Korea University Guro Hospital (1) · Massachusetts General Hospital (1) · National Cancer Center, Korea (1) · National Cancer Centre, Singapore (1) · National University Hospital, Singapore (1) · Peking University People's Hospital (1) · Qingdao Central Hospital (1)
China (11) · South Korea (4) · Germany (2) · Singapore (2) · United States (2) · Hong Kong (1) · Malaysia (1) · Thailand (1)
Amanda Tufman, Prof. Dr. (1) · Bai Chunmei, MD (1) · Daniel Tan, BSc, MBBS, PhD (1) · Fan Yanf, M.D. (1) · Fang Jian, MD (1) · Helong Zhang, MD (1) · Ji-Youn Han, Ph.D (1) · Jiao Shunchang, MD (1) · Laura A Petrillo, MD (1) · Li Zhang, Professor (1) · Liu Wei, MD (1) · Petros Christopoulos, MD (1) · Stephen P Anthony, DO (1) · Sung Yong Lee, MD, Ph.D. (1)
PMID 32606956, PMID 33067126, PMID 36268845, PMID 41583476, PMID 42442920, PMID 42660909
K08CA263549 (1)